Skip to main content
. 2019 Sep 20;14(9):e0222102. doi: 10.1371/journal.pone.0222102

Fig 5. Survival analysis (Kaplan–Meier estimate and log-rank test) of patients for thrombophilic risk factors (TRFs) in detail.

Fig 5

(A) MTHFR: Survival tended to be shorter in patients with only a MTHFR mutation (MTHFR only) than in patients without a TRF, but without statistical significance, whereas survival was significantly shorter in patients with a further coagulation disorder (MTHFR + further TRF) than in patients without a TRF (P<0.02). (B) Factor V (FV) mutation: Survival was not significantly different between patients with only a FV mutation (FV only) and patients without a TRF, whereas survival was significantly shorter in patients with a further coagulation disorder (FV + further TRF) than in patients without a TRF (P<0.05). (C) Antithrombin (AT) deficiency: Survival was not significantly different between patients with only an AT deficiency (AT only) and patients without a TRF, whereas survival tended to be shorter in patients with a further coagulation disorder (AT + further TRF) than in patients without a TRF (P = 0.054). (D) Antiphospholipid (APL) antibodies: Survival tended to be shorter in patients with only APL antibodies (APL only) than in patients without a TRF, but without statistical significance, whereas survival was significantly shorter in patients with a further coagulation disorder (APL + further TRF) than in patients without a TRF (P<0.05).